Department of Neuroscience for Drug Discovery, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida-Shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan.
Bioorg Med Chem Lett. 2010 Mar 1;20(5):1718-20. doi: 10.1016/j.bmcl.2010.01.057. Epub 2010 Jan 20.
We synthesized a series of N(1)-substituted norcymserine derivatives 7a-p and evaluated their anti-cholinesterase activities. In vitro evaluation showed that the pyridinylethyl derivatives 7m-o and the piperidinylethyl derivative 7p improved the anti-butyrylcholinesterase activity by approximately threefold compared to N(1)-phenethylnorcymserine (PEC, 2). A quantitative structure-activity relationship (QSAR) study indicated that logS might be a key feature of the improved compounds.
我们合成了一系列 N(1)-取代的去甲辛可宁环碱衍生物 7a-p,并评估了它们的抗胆碱酯酶活性。体外评价表明,吡啶基乙基衍生物 7m-o 和哌啶基乙基衍生物 7p 与 N(1)-苯乙基去甲辛可宁环碱(PEC,2)相比,大约提高了三倍的抗丁酰胆碱酯酶活性。定量构效关系(QSAR)研究表明,logS 可能是改善化合物的关键特征。